Monoklonal Antikor (Hedef Ajan) Kullanan Kanser Hastalarının Semptom Sıklıkları Ve Yaşam Kalitelerinin İncelenmesi

Examination of Symptom Frequency and Quality of Life of Cancer Patients Using Monoclonal Antibody (Target Agent)

Özet

Amaç: Monoklonal antikorlar (hedef ajan) son yıllarda pekçok hastalığın tedavisinde kullanılmaktadır. Kanserli hastaların tedavisinde de yaygın olarak kullanılmaya başlanılan bu ilaçlar başarılı sonuçlar göstermektedir. Bu çalışmanın amacı monoklonal antikor kullanan kanserli hastaların semptom sıkları ve yaşam kalitelerinin incelenmesidir. Yöntem: 28 Şubat- 31 Mayıs 2017 tarihleri arasında kemoterapi ünitesine başvuran, 18 yaşından büyük olan, 103 hasta ile görüşülmüştür. Hasta Soru Formu, Memorial Semptom Değerlendirme Skalası (MSAS), ve Yaşam Kalitesi İndeksi –Kanser Versiyonu-III (Quality of Life Index–Cancer Version-III (QOL-CV) ) kullanılmıştır. Bulgular: Katılımcıların %70.9’u kadın, %30.1’i ilkokul mezunu, %74.8’i evli, %85.4’ü çalışmayan bireylerdir. Hastaların total MSAS puanı 0.69, QOL toplam ölçek puanı 22.15 olarak hesaplanmıştır. MSAS- Fiziksel alt boyut puanı ile eğitim ve monoklonal çeşitleri arasında ilişki saptanmıştır. QOL toplam ve alt boyutlarının pek çok bağımsz değişken ile arasında anlamlı bir ilişki bulunmuştur. Sonuç: Monoklonal antikor kullanan kanser hastalarının semptomlarla ilgili sıklık, şiddet ve sıkıntıları arttığında yaşam kalitelerinde nispeten olumsuz değişiklikler görülmektedir.

Abstract

Aim : Monoclonal antibodies (target agent) have been used in the treatment of many diseases in recent years. These drugs, which have been widely used in the treatment of cancer patients, show successful results. The aim of this study is to examine the symptom frequencies and quality of life of cancer patients using monoclonal antibodies. Method: Between February 28 and May 31, 2017, 103 patients, aged 18 years or older, who were referred to the chemotherapy unit, were interviewed. Patient Questionnaire, Memorial Symptom Assessment Scale (MSAS), and Quality of Life Index-Cancer Version-III (QOL-CV) were used. Findings: 70.9% of the participants were women, 30.1% were primary school graduates, 74.8% were married and 85.4% were not working. Total MSAS score of the patients was calculated as 0.69, QOL total scale score was 22.15. MSAS- Physical subscale score and education and monoclonal varieties. QOL total and sub-dimensions were found to be significantly correlated with many independent variables. Result: Cancer patients using monoclonal antibodies have relatively negative changes in their quality of life when the incidence, severity, and frequency of symptoms increase.: Monoclonal antibodies (target agent) have been used in the treatment of many diseases in recent years. These drugs, which have been widely used in the treatment of cancer patients, show successful results. The aim of this study is to determine the frequency of symptoms and the quality of life of cancer patients using monoclonal antibodies. Method: Between February 28 and May 31, 2017, 103 patients, aged 18 years or older, who were referred to the chemotherapy unit, were interviewed. Patient Questionnaire Memorial Symptom Assessment Scale (MSAS), and Quality of Life Index-Cancer Version-III (QOL-CV) were used. Conclusion: 70.9% of the participants were women, 30.1% were primary school graduates, 74.8% were married and 85.4% were not working. Total MSAS score of the patients was calculated as 0.69, QOL total scale score was 22.15. MSAS- Physical subscale score and education and monoclonal varieties. QOL total and sub-dimensions were found to be significantly correlated with many independent variables. Result: Cancer patients using monoclonal antibodies have relatively negative changes in their quality of life when the incidence, severity, and frequency of symptoms increase.